Cinacalcet Hydrochloride
Product Images NDC 70436-007

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cinacalcet Hydrochloride (NDC 70436-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cinacalcet-fig-1.jpg (Cinacalcet Fig 1)

A line graph comparing iPTH (pg/mL) levels over 26 weeks between placebo and cinacalcet hydrochloride tablets. The graph shows iPTH values on the vertical axis and weeks on the horizontal axis. Cinacalcet HCl treatment is represented by a solid line with filled circle markers, showing a downward trend, while placebo is shown with a dashed line and open circle markers, indicating relatively stable iPTH levels.*

FDA Label Image

Cinacalcet-fig-2.jpg (Cinacalcet Fig 2)

A line graph comparing calcium-phosphorus product levels (Ca x P in mg/dL) squared over 26 weeks between placebo and Cinacalcet HCl tablets. The plot shows distinct trends for each group, with Cinacalcet HCl tablets represented by solid circles and placebo by open circles, including error bars for variability at each time point.*

FDA Label Image

Cinacalcet-fig-3.jpg (Cinacalcet Fig 3)

A line graph depicting calcium levels (mg/dL) over time in weeks for patients with parathyroid carcinoma. The x-axis marks weeks from baseline through titration (B to EOT) and maintenance phases, with decreasing patient counts noted below. The y-axis shows calcium levels ranging from 8 to 16 mg/dL. Data points include error bars indicating variability.*

FDA Label Image

Cinacalcet-fig-4.jpg (Cinacalcet Fig 4)

A line graph depicting calcium levels (mg/dL) over weeks during titration and maintenance phases in patients with intractable pHPT. The x-axis shows time in weeks from baseline (B) through 80 weeks, with data points connected by lines and error bars indicating variability. The y-axis measures calcium concentration ranging from 8 to 16 mg/dL. Patient counts at each time point are noted below the x-axis.*

FDA Label Image

Cinacalcet-str.jpg (Cinacalcet Str)

Chemical structure of cinacalcet hydrochloride, depicting its molecular framework including trifluoromethyl and naphthyl groups with associated hydrochloride salt.*

FDA Label Image

70436-007-04 (Image 01)

Label for Cinacalcet Hydrochloride Tablets, 30 mg, by Slate Run Pharmaceuticals. The label indicates a 30-tablet count and includes dosage and storage instructions. Manufactured by Piramal Enterprises Limited, with distribution by Slate Run Pharma, LLC, Columbus, Ohio. The NDC code is 70436-007-04.*

FDA Label Image

70436-008-04 (Image 02)

The label for Cinacalcet Hydrochloride Tablets, 60 mg strength, from Slate Run Pharmaceuticals. The label includes a note that each film-coated tablet contains cinacalcet hydrochloride equivalent to 60 mg cinacalcet. It indicates a package size of 30 tablets. Manufacturer information shows Piramal Enterprises Limited in India. Directions about storage and dispensing, as well as a caution to keep medication out of reach of children, are also present.*

FDA Label Image

70436-009-04 (Image 03)

Label for Cinacalcet Hydrochloride Tablets, 90 mg, by Slate Run Pharmaceuticals. The label includes the NDC 70436-009-04, indicates the product is prescription only, and is for a package of 30 tablets. It provides storage instructions, dispensing container info, manufacturing details from Piramal Enterprises Limited in India, and distribution by Slate Run Pharmaceuticals, Columbus, Ohio.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.